How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Boron Neutron Capture Therapy Targeted Boron Drugs Market
- By Drug Type: Boronophenylalanine (BPA), Sodium Borocaptate (BSH), Boronated Porphyrins, Boronated Monoclonal Antibodies, Boronated Liposomes
- By Therapeutic Application: Glioblastoma Multiforme, Head and Neck Cancers, Melanoma, Lung Cancer, Liver Cancer
- By Drug Delivery Mechanism: Intravenous Injection, Oral Administration, Intratumoral Injection, Convection-Enhanced Delivery
- By Chemical Structure: Amino Acid Derivatives, Carborane-Based Compounds, Porphyrin-Based Compounds, Monoclonal Antibody Conjugates
- By Development Stage: Preclinical, Clinical Trials Phase I, Clinical Trials Phase II, Clinical Trials Phase III, Commercialized
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Boronophenylalanine (BPA) leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Boron Neutron Capture Therapy Targeted Boron Drugs Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Therapeutic Application 5
Drug Delivery Mechanism 4
Chemical Structure 4
Development Stage 5
Companies profiled
Steba Biotech
Nippon Kayaku Co. Ltd.
Boron Molecular
Sumitomo Chemical Company
Limited
Panagene Inc.
Neutron Therapeutics Inc.
Nordion Inc.
IBA (Ion Beam Applications)
Hitachi Ltd.
Mitsubishi Heavy Industries Ltd.
Nordion (a Sotera Health company)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Steba Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Nippon Kayaku Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boron Molecular
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sumitomo Chemical Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Panagene Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Neutron Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nordion Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →IBA (Ion Beam Applications)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Hitachi Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Mitsubishi Heavy Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Nordion (a Sotera Health company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,179M by 2033 · 6.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Boronophenylalanine (BPA)39.5
- Sodium Borocaptate (BSH)19.0
- Boronated Porphyrins10.4
- Boronated Monoclonal Antibodies17.7
- Boronated Liposomes13.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,247M → $2,098M · 6.7%
Europe$869.2M → $1,435M · 6.5%
Asia Pacific$793.6M → $1,175M · 5.0%
Latin America$491.3M → $794.7M · 6.2%
Middle East and Africa$377.9M → $686.8M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.292026
6.302027
6.322028
6.332029
6.352030
6.352031
6.372032
6.372033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Steba Biotech15.5
- Nippon Kayaku Co. Ltd.22.7
- Boron Molecular6.0
- Sumitomo Chemical Company10.8
- Limited7.1
- Panagene Inc.10.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type35.4%
Therapeutic Application20.0%
Drug Delivery Mechanism12.6%
Chemical Structure11.6%
Development Stage20.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe23.2
- Asia Pacific19.0
- Latin America12.8
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Steba Biotech | 77 | 78 | 81 | 98 | 84 | 85 | 84 |
| Nippon Kayaku Co. Ltd. | 88 | 77 | 83 | 85 | 90 | 80 | 84 |
| Boron Molecular | 84 | 78 | 80 | 79 | 72 | 81 | 79 |
| Sumitomo Chemical Company | 65 | 75 | 72 | 78 | 73 | 74 | 73 |
| Limited | 69 | 52 | 61 | 68 | 73 | 63 | 64 |
| Panagene Inc. | 71 | 68 | 46 | 57 | 46 | 48 | 56 |
| Neutron Therapeutics Inc. | 65 | 49 | 49 | 59 | 41 | 59 | 54 |
| Nordion Inc. | 45 | 60 | 35 | 35 | 56 | 41 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Steba Biotech
- Nippon Kayaku Co. Ltd.
- Boron Molecular
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Steba Biotech | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Nippon Kayaku Co. Ltd. | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Boron Molecular | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Sumitomo Chemical Company | − | ◐ | ✓ | ◐ | ◐ | ✓ |
| Limited | − | − | − | − | ✓ | ◐ |
| Panagene Inc. | − | ◐ | − | ◐ | − | − |
| Neutron Therapeutics Inc. | ◐ | − | − | − | − | − |
| Nordion Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Steba Biotech84
2Nippon Kayaku Co. Ltd.84
3Boron Molecular79
4Sumitomo Chemical Company73
5Limited64
6Panagene Inc.56
7Neutron Therapeutics Inc.54
8Nordion Inc.45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Steba BiotechNippon Kayaku Co. Ltd.Boron Molecular
Challenger1
Strong scale, closing on the leaders.
Sumitomo Chemical Company
Contender1
Focused players with pockets of strength.
Limited
Niche3
Specialists in a single segment or region.
Panagene Inc.Neutron Therapeutics Inc.Nordion Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Boron Neutron Capture Therapy Targeted Boron Drugs Market — a $195M beachhead inside a $3.49B market.
Beachhead (SOM)$195Mobtainable near-term
Serviceable (SAM)$1.33Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Boronophenylalanine (BPA)
Best fit — highest urgency & budget in Drug Type.
Economic buyer78 fit
Sodium Borocaptate (BSH)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Boronated Porphyrins
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Delivery Mechanism
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Boron Neutron Capture Therapy Targeted Boron Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation15%
Closed-won6%
$13.9KCAC
$74KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Boron Neutron Capture Therapy Targeted Boron Drugs Market is a resilient opportunity — $717M by 2033, compounding at 3.6%.
TAM · 2025$540Mtoday
TAM · 2033$717Mforecast
CAGR3.6%2027–2033
Cumulative$5.62Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$717MTotal addressable market
SAM$261MServiceable available market
SOM$46MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.6% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$717MLarge & growingTAM by 2033 at 3.6% CAGR
$261MServiceable nowreachable with today’s model
$46MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$559MBear2.3% CAGR
$717MBase3.6% CAGR
$918MBull4.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Boron Neutron Capture Therapy Targeted Boron Drugs Market — a $8.36B market by 2033. Plan: grow share from 10.2% to 18.0%.
Market size · 2033$8.36Btotal addressable
Market CAGR7.7%2027–2033
Target share18.0%from 10.2% today
Revenue ambition$1.50Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.2% | 18.0% | At risk |
| Revenue | $778M | $1.50B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.3% | 38.9% | At risk |
| Customer retention | 85.4% | 96.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $179M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Boron Neutron Capture Therapy Targeted Boron Drugs Market conversation — a $6.29B market you can size, segment and defend in minutes.
Market size · 2033$6.29Btotal opportunity
Growth6.1%CAGR to 2033
Addressable buyers1,772+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 3 mopayback period
$48K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Steba BiotechNippon Kayaku Co. Ltd.Boron MolecularSumitomo Chemical CompanyLimitedPanagene Inc.Neutron Therapeutics Inc.Nordion Inc.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Boron Neutron Capture Therapy Targeted Boron Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Boron Neutron Capture Therapy Targeted Boron Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Boron Nitrate Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBoron Nitride Ceramic Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBoron Nitride Ceramic Release Agent Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportBoron Nitride Nanotube Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBoron Nitride Target Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBoron Ore Concentrate Powder Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBoron Phenolic Resin Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBoron Reinforced Aluminum Matrix Composites Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportBoron Tribromide Dimethyl Sulfide Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBoron Trifluoride Acetonitrile Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBoron Trifluoride Catalyst Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBoron Trifluoride Counter Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.